Journal Browser

Journal Browser

Cell Lineage Choice during Haematopoiesis 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 5654

Special Issue Editor

E-Mail Website
Guest Editor
School of Biomedical Sciences, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Interests: the use of synthetic retinoids and vitamins D as drug substances; cancer and normal stem cells; anticancer therapies; blood cell development; abnormalities in cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second volume of our previous Special Issue “Cell Lineage Choice during Hematopoiesis: A Commemorative Issue in Honor of Professor Antonius Rolink”.

For more than 30 years, we seemed to have a very clear picture of how the hematopoietic stem cell (HSC) gives rise to the many different types of blood and immune cells. In the classic lineage tree model, HSC follows a prescribed route to each of the end cell types and gradually restricts their alternative choices via a series of intermediate oligo-potent progenitor cells. Recent findings have challenged these principles, leading to a very different viewpoint whereby a continuum of each fate option is open to HSCs. Thus, HSCs have lineage biases/affiliations and progenitor cells in bone marrow are either pluripotent or unipotent. Thus, HSCs can make an immediate choice without traversing a series of intermediate progenitors to progressively close down developmental options. Developing cells can move sideways to adopt an alternative fate. This Special Issue will examine the shift toward a new architecture for the blood cell system and how the development of such cells is controlled.


Dr. Geoffrey Brown
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • The haematopietic stem cell
  • The nature of haematopoietic progenitors
  • Decision-making during haematopoiesis
  • Modelling haematopoiesis
  • Culture and in vivo model systems for studying haematopoiesis
  • T lymphocyte development
  • B lymphocyte decelopment
  • The diversity of the mature types of blood cells
  • Molecular controls on haematopoiesis
  • Haematopoietic growth factors
  • Differentiating agents
  • Implications of our understanding of haematopoiesis to leukaemia

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


15 pages, 999 KiB  
Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells
by Geoffrey Brown
Int. J. Mol. Sci. 2021, 22(18), 9667; https://doi.org/10.3390/ijms22189667 - 7 Sep 2021
Cited by 10 | Viewed by 5052
In principle, an oncogene is a cellular gene (proto-oncogene) that is dysfunctional, due to mutation and fusion with another gene or overexpression. Generally, oncogenes are viewed as deregulating cell proliferation or suppressing apoptosis in driving cancer. The cancer stem cell theory states that [...] Read more.
In principle, an oncogene is a cellular gene (proto-oncogene) that is dysfunctional, due to mutation and fusion with another gene or overexpression. Generally, oncogenes are viewed as deregulating cell proliferation or suppressing apoptosis in driving cancer. The cancer stem cell theory states that most, if not all, cancers are a hierarchy of cells that arises from a transformed tissue-specific stem cell. These normal counterparts generate various cell types of a tissue, which adds a new dimension to how oncogenes might lead to the anarchic behavior of cancer cells. It is that stem cells, such as hematopoietic stem cells, replenish mature cell types to meet the demands of an organism. Some oncogenes appear to deregulate this homeostatic process by restricting leukemia stem cells to a single cell lineage. This review examines whether cancer is a legacy of stem cells that lose their inherent versatility, the extent that proto-oncogenes play a role in cell lineage determination, and the role that epigenetic events play in regulating cell fate and tumorigenesis. Full article
(This article belongs to the Special Issue Cell Lineage Choice during Haematopoiesis 2.0)
Show Figures

Figure 1

Back to TopTop